TNRX 257
Alternative Names: TNRX-257Latest Information Update: 19 Jun 2023
At a glance
- Originator Tentarix Biotherapeutics
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies
- Mechanism of Action CD223 antigen inhibitors; Interleukin-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer